Inclusion Criteria:

- Males or females aged >/= 18 years

- Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucinous or
clear cell tumors) or Adenocarcinoma of the prostate

- At least 1 unidimensional measurable lesion (suitable for RECIST evaluation) or for
patients without measurable disease, CA 125 levels >/= 2 times the upper limit of
normal (ULN) within 3 months and confirmed within 2 weeks prior to first infusion
(ovarian cancer) or PSA value >/= 5 ng/mL (HRPC).

- Progression of disease (HRPC) despite adequate androgen-inhibiting hormone therapy.

- Progression of disease (Ovarian Cancer) or symptomatic relapse after previous therapy
(elevated CA125 levels alone are insufficient for inclusion) WHO performance status
0 to 1

- No clinical residual neuropathy (CTCAE Grade 0 at baseline)

- Adequate recovery from previous surgery, radiation, and chemotherapy (excluding
alopecia)

- Adequate function of major organs and systems.

- Survival expectation =3 months

- Histologically or cytologically proven:

1. Epithelial ovarian, peritoneal cavity or Fallopian tube cancer (except mucionous
cell tumors or clear cell tumors that have a clear cell component of >33%)

Exclusion Criteria:

- Symptomatic brain metastases requiring whole- brain irradiation

- Any concomitant malignancy: the following exceptions are allowed: Non-melanoma skin
cancer, Carcinoma in situ of the cervix, Malignancy with definitive treatment >/= 5
years ago without relapse.

- Diabetes mellitus (even if controlled only by special diet)

- History of chronic hepatitis B or C, or known HIV infection

- Seizure disorder requiring medication (such as steroids or anti-epileptics)

- Inability to swallow oral medications

- Prior treatment with epothilones

- Concomitant use of neurotoxic drugs

- Concomitant use of compounds that have potentially positive effects towards symptoms
of neuropathy